Inverna Therapeutics

Private

OdenseHealthcare & Life Scienceshttps://www.invernatx.com/

Last Round

Grant

Oct 9, 2025

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Inverna Therapeutics is a biotechnology company that is a developer of a next-generation ribonucleic acid splicing modulation platform intended to transform patient outcomes in severe genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

RNA splicing modulationoligonucleotide therapypseudo-exon activationantisense oligonucleotideASOsplice switchingHuntington's diseaseParkinson's diseaseRNA therapyneurodegenerative diseasedrug discovery platformgenetic diseaseallele-specific targetingLRRK2 targetpre-clinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Inverna Therapeutics Comparables

Compare Inverna Therapeutics with similar companies based on industry and business-model similarity.

Inverna Therapeutics comparables — related companies by embedding similarity
Company	Similarity	Market Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Inverna Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Oct 9, 2025
Seed	Jan 7, 2025

View all Funding Rounds

Key People

Founding team and executive leadership

Poul Sørensen

CEO

Executive Team

Inverna Therapeutics Investors

Notable investors and investment history

Inverna Therapeutics investors
Investor	Rounds
University of Southern Denmark	Seed
The Michael J. Fox Foundation for Parkinson's Research	Grant

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 17, 2026
Monthly visitors increased 139% MoM.
Oct 9, 2025
Received grant from The Michael J. Fox Foundation.

View all signals

Inverna Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Inverna Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Inverna Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOdense

Employee Range6

Year Founded2024

Last FundingOct 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.